Navigation Links
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Date:1/13/2009

dhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the relevance of EpCAM as a drug target, the efficacy and intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "could," "may," "appear," "promising," "potential," "planned," or the negative of those words or other similar words to be uncertain
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
2. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
3. Wound Management Technologies, Inc. Announces a Published Case Study
4. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
5. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
8. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
9. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... induce stress,but caring for children with diabetes this time ... and caregivers can visit, http://www.abbottdiabetescare.com to participate in ... how to best manage a child,s,diabetes during the holidays, ... ,Diabetes Fit Food, booklet for tips on healthy eating. ...
... REDWOOD CITY, Calif., Nov. 7 Threshold,Pharmaceuticals, Inc. ... for,the third quarter ended September 30, 2007. Net ... million compared to $16.7 million for the third ... development of our hypoxia-activated prodrug,platform for the treatment ...
... 13 at 1:30 p.m. (Pacific); ... at http://www.adventrx.com , SAN DIEGO, Nov. 7 ... research and development company,focused on commercializing proprietary product candidates ... financial results for,the three-month and nine-month periods ended September ...
Cached Biology Technology:New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 3Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 4Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... type of brain cancer, undergo neurosurgery to remove the ... largely on how rapidly the cancer recurs. Even though ... it is difficult to determine with certainty whether cancer ... aggressive treatment. Now a team from the University ...
... ACTON, Mass., Jan. 24, 2012 Psychemedics Corporation (NASDAQ: ... global leader for 25 years, announced today that the ... No. 8,084,215, to the company.  This patent focuses on ... without destroying the drugs.  The new patented method can ...
... 23, 2012) - With growing concern that excessive levels of ... pressure, kidney disease and diabetes researchers at the University of ... of Florida, set out to see if two common sweeteners in ... first few hours after ingestion. The study, recently published in ...
Cached Biology News:Team finds new way to image brain tumors and predict recurrence 2Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing 2CU School of Medicine researchers look at effects of 2 common sweeteners on the body 2
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... tissue microarrays are derived from frozen embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... slides. Sections are large (3-5mm in diameter) ...
... are derived from Paraffin embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... Sections are large (3-5mm in diameter) in ...
... Precision-designed for Optimal Microdissection , ... enable the precise and rapid extraction of ... and cytology samples with Laser Capture Microdissection., ... for Downstream Molecular Analysis , All CapSure ...
Biology Products: